Richard Thomas Menziuso, Principal Accounting Officer of Altimmune, Inc., filed a Form 4 on November 18, 2026, disclosing a purchase of 10,000 shares of Altimmune common stock on that same date.

Key Highlights

  • Reporting person: Richard Thomas Menziuso, identified as Principal Accounting Officer of Altimmune, Inc. (NASDAQ:ALT)
  • Transaction type: Purchase (transaction code P) of common stock, par value $0.0001
  • Shares acquired: 10,000 shares acquired on November 18, 2026
  • Price paid: $1.4187 per share
  • Resulting ownership: 10,000 shares of common stock beneficially owned directly following the transaction
  • Filing form: Signed by Gregory Weaver as Attorney-in-Fact on November 18, 2026

Altimmune Principal Accounting Officer Reports Open-Market Stock Purchase

According to the Form 4 filing, Richard Thomas Menziuso, serving as Principal Accounting Officer of Altimmune, Inc. (NASDAQ:ALT), acquired 10,000 shares of the company's common stock (par value $0.0001 per share) on November 18, 2026. The transaction was coded as a purchase (code "P") and was reported as a direct ownership position. The price per share disclosed in the filing is $1.4187.

Following this transaction, the filing indicates that Menziuso holds 10,000 shares of Altimmune common stock directly. No prior holdings are listed in Table I, and no derivative securities were reported in Table II of the filing. The form was signed by Gregory Weaver as Attorney-in-Fact for the reporting person, also on November 18, 2026. No amendment date is indicated, meaning this appears to be an original filing rather than a correction to a prior report.

The filing was submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and certain shareholders to report changes in their beneficial ownership of company securities. No Rule 10b5-1 plan checkbox was indicated as applying to this transaction, according to the filing.

What Was Disclosed

The filing reports a single open-market purchase of 10,000 shares of Altimmune common stock at $1.4187 per share by Principal Accounting Officer Richard Thomas Menziuso on November 18, 2026, resulting in direct beneficial ownership of 10,000 shares.